Heart disease is among the most common causes of death in older dogs. Congestive heart failure (CHF) — when the heart can no longer maintain adequate circulation — represents a critical welfare challenge requiring skilled management to maintain quality of life.
Myxomatous mitral valve disease (MMVD): The most common cardiac disease in dogs, particularly in small breeds. The mitral valve leaflets degenerate and thicken, causing regurgitation (blood flowing backwards) and eventually CHF. Cavalier King Charles Spaniels are genetically predisposed and affected earlier in life. The ACVIM (American College of Veterinary Internal Medicine) consensus guidelines recommend starting pimobendan before CHF develops in dogs with specific echocardiographic criteria, significantly delaying onset.
Dilated cardiomyopathy (DCM): Primarily affects large and giant breeds (Dobermanns, Irish Wolfhounds, Great Danes, Boxers). The heart muscle weakens and dilates, reducing contractile force. DCM often presents with sudden cardiac arrhythmia before obvious CHF signs develop. Dobermanns are particularly prone to occult DCM with sudden death from ventricular arrhythmia.
Left-sided CHF causes pulmonary oedema — fluid accumulation in the lungs. Signs: exercise intolerance, coughing (particularly at night or after exercise), increased respiratory rate, dyspnoea (laboured breathing), cyanosis (blue-tinged gums) in severe cases. Right-sided CHF causes ascites (fluid in the abdomen), pleural effusion, and peripheral oedema. Syncope (fainting) occurs with arrhythmias.
CHF causes chronic suffering when untreated or undertreated. Dyspnoea — difficulty breathing — is profoundly aversive. Reduced exercise tolerance frustrates active dogs. Weakness, fatigue, and reduced engagement with the environment reflect poor quality of life. The welfare goal is to maintain the dog in a compensated state where clinical signs are controlled and quality of life is maintained.
CHF management uses multiple drugs targeting different aspects of the disease. Furosemide (and other diuretics) removes excess fluid from the lungs and body. Pimobendan improves cardiac contractility and reduces cardiac workload — the cornerstone of CHF management in MMVD and DCM. ACE inhibitors (enalapril, benazepril) reduce cardiac workload through vasodilation. Spironolactone provides additional diuretic effect and cardioprotection. Antiarrhythmics (mexiletine, sotalol, amiodarone) manage life-threatening arrhythmias in DCM.
Quality of life assessment in CHF dogs focuses on: respiratory comfort (respiratory rate at home monitoring), activity and engagement, appetite, and sleep quality. Owner respiratory rate monitoring (counting breaths per minute during sleep, normal <30) provides an objective home welfare measure that guides dose adjustments. As disease progresses and becomes refractory to medical management, quality of life discussions with veterinary guidance support owners in recognising when palliative care transitions to end-of-life decisions.
← Back to Animal Welfare Hub